BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care

GlobeNewsWire • Feb 19, 2026

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers whose patients have coverage under Evernorth and Cigna Healthcare® plans. The Evernorth press release stated that the change will be effective on March 6, 2026.

GlobeNewsWire • Feb 18, 2026

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors

GlobeNewsWire • Feb 17, 2026

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients

GlobeNewsWire • Jan 21, 2026

BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants

GlobeNewsWire • Jan 12, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients

GlobeNewsWire • Jan 7, 2026

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.

Zacks Investment Research • Dec 23, 2025

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older

GlobeNewsWire • Dec 22, 2025

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

Seeking Alpha • Dec 1, 2025

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay's growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer, Radial), who will discuss the significant unmet need for various conditions and his clinical experience utilizing Deep TMS™, and Michael Gershenzon, CEO of Stella MSO, a management services organization servicing more than 20 mental health clinics across the U.S. and Israel, who will discuss his experience working with BrainsWay on BrainsWay's strategic minority-stake investment in Stella. To register, click here.

GlobeNewsWire • Nov 25, 2025